Limertinib
Limertinib is Aosaikang's third-generation EGFR inhibitor, approved in China in 2024 for lung cancer with the T790M resistance mutation after earlier EGFR drugs, and in phase 3 trials for first-line use.
Overview
Jiangsu Aosaikang's limertinib (ASK120067) was approved by the NMPA in 2024 for locally advanced or metastatic EGFR T790M-positive non-small cell lung cancer after progression on earlier EGFR inhibitors, joining osimertinib, furmonertinib and befotertinib among China's third-generation options. A phase 3 first-line trial against gefitinib is registered.
A covalent inhibitor of EGFR sensitising and T790M resistance mutations that spares wild-type EGFR, the osimertinib class. Connects to EGFR.
1.Limertinib slips into a pocket on EGFR.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Compare all products across the US, EU, UK, Japan, China and Australia →
Approvals
| Region | Year | Indication |
|---|---|---|
| CN | 2024 | Locally advanced or metastatic EGFR T790M-mutant non-small cell lung cancer after prior EGFR inhibitor therapy |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"Limertinib" OR ABSTRACT:"Limertinib" OR TITLE:"ASK120067" OR ABSTRACT:"ASK120067") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Limertinib, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentJS111
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
- TreatmentVRN110755
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
- TreatmentTQB6411
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
- TreatmentJMT101
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
- TreatmentGlumetinib
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
- TreatmentHS-20117
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
- TreatmentSilevertinib
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
- TreatmentHMBD-001
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.